表紙：RNA治療薬市場（mRNA治療薬およびワクチン、RNAi治療薬、RNAアプタマー）における機会：イノベーター動向、製品オファリング分析、企業のヘルスインデックス、主な買収標的

市場調査レポート

商品コード

1241326

RNA治療薬市場（mRNA治療薬およびワクチン、RNAi治療薬、RNAアプタマー）における機会：イノベーター動向、製品オファリング分析、企業のヘルスインデックス、主な買収標的

Investor Series: Opportunities in RNA Therapeutics Market (mRNA Therapeutics & Vaccines, RNAi Therapeutics, & RNA Aptamers): Focus on Innovators Landscape, Analysis of Product Offerings & Company Health Indexing, Key Acquisition Targets

出版日: 2023年03月14日 | 発行: Roots Analysis

| ページ情報: 英文 174 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 1,899 297,687円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 3,499 548,503円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 4,599 720,939円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 5,999 940,403円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界のRNA治療薬市場について調査し、市場およびRNA治療薬の概要とともに、イノベーター動向、資金調達と投資分析、市場予測と機会分析、および市場に参入する企業のプロファイルなどを提供しています。

LIST OF TABLES

Table 6.1. Key Innovators in the RNA Therapeutics Market
Table 7.1. Products Offered by Innovators in the RNA Therapeutics Market
Table 7.2. RNA Therapeutics Developers: Company Health Indexing (I/V)
Table 7.3. RNA Therapeutics Developers: Company Health Indexing (II/V)
Table 7.4. RNA Therapeutics Developers: Company Health Indexing (III/V)
Table 7.5. RNA Therapeutics Developers: Company Health Indexing (IV/V)
Table 7.6. RNA Therapeutics Developers: Company Health Indexing (V/V)
Table 11.1. Valuation of Public Companies: Sample Dataset
Table 11.2. Company Valuation: Based on Company Size
Table 11.3. Company Valuation: Based on Latest Stage of Financing
Table 11.4. Company Valuation: Based on Company Size and Latest Stage of Funding
Table 12.1. Fundamental Financial Analysis: Information on Publicly Listed RNA Therapeutics Developers
Table 12.2. Technical Financial Analysis: Information on Publicly Listed RNA Therapeutics Developers
Table 17.1. RNA Therapeutics Developers: Likely Acquisition Targets (Company Strength)
Table 17.2. RNA Therapeutics Developers: Likely Acquisition Targets (Value Proposition)

LIST OF FIGURES

Figure 5.1. RNA Therapeutics: Key Definitions and Background
Figure 5.2. RNA Therapeutics: Types of Therapies and Key Industry Players
Figure 5.3. RNA Therapeutics: Key Historical Developments
Figure 5.4. RNA Therapeutics: Key Strategic Initiatives of Industry Players
Figure 5.5. RNA Therapeutics: Key Marketed Products and Current Unmet Needs
Figure 6.1. Innovators Landscape: Distribution by Year of Establishment
Figure 6.2. Innovators Landscape: Distribution by Type of Venture
Figure 6.3. Innovators Landscape: Distribution by Company Size
Figure 6.4. Innovators Landscape: Distribution by Geography
Figure 7.1. Products Landscape: Distribution of Innovators by Number of Products
Figure 7.2. Products Landscape: Distribution by Type of Products
Figure 7.3. Products Landscape: Distribution of Products by Phase of Development
Figure 7.4. Products Landscape: Distribution of Products by Route of Administration
Figure 7.5. Products Landscape: Distribution of Products by Therapeutic Area
Figure 8.1. Therapy-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.2. Therapy-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.3. Developer-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.4. Developer-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.5. Technology-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.6. Technology-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.7. Patient-related Aspect: Distribution of Companies by Value Offered and Years of Experience
Figure 8.8. Patient-related Aspect: Distribution of Companies Offering Very High Value
Figure 8.9. Summary of Value Proposition Analysis
Figure 9.1. Competitiveness Analysis: Companies based in North America (Peer Group I)
Figure 9.2. Competitiveness Analysis: Companies based in Europe (Peer Group II)
Figure 9.3. Competitiveness Analysis: Companies based in Asia and Rest of the World (Peer Group III)
Figure 10.1. Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances and Amount Invested, 2011-2022
Figure 10.2. Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.3. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding
Figure 10.4. Funding and Investment Analysis: Distribution of Instances and Amount Invested by Region
Figure 10.5. Funding and Investment Analysis: Most Active Players by Number of Instances
Figure 10.6. Funding and Investment Analysis: Most Active Players by Amount Raised
Figure 10.7. Awards / Grants: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.8. Awards / Grants: Distribution of Amount Invested by Region
Figure 10.9. Awards / Grants: Most Active Investors by Amount Invested
Figure 10.10. Seed Funding: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.11. Seed Funding: Distribution of Amount Invested by Region
Figure 10.12. Seed Funding: Most Active Investors by Amount Invested
Figure 10.13. Venture (Series A): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.14. Venture (Series A): Distribution of Amount Invested by Region
Figure 10.15. Venture (Series A): Most Active Investors by Amount Invested
Figure 10.16. Venture (Series B): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.17. Venture (Series B): Distribution of Amount Invested by Region
Figure 10.18. Venture (Series B): Most Active Investors by Amount Invested
Figure 10.19. Venture (Series C): Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.20. Venture (Series C): Distribution of Amount Invested by Region
Figure 10.21. Venture (Series C): Most Active Investors by Amount Invested
Figure 10.22. Venture (Series D, E, F, G, H, and Unknown) Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.23. Venture (Series D, E, F, G, H, and Unknown): Distribution of Amount Invested by Region
Figure 10.24. Venture (Series D, E, F, G, H, and Unknown): Most Active Investors by Amount Invested
Figure 10.25. Public Offerings: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.26. Public Offerings: Distribution of Amount Invested by Region
Figure 10.27. Public Offerings: Publicly Listed Players
Figure 10.28. Private Placements: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.29. Private Placements: Distribution of Amount Invested by Region
Figure 10.30. Private Placements: Most Active Investors by Amount Invested
Figure 10.31. Debt Financing: Cumulative Number of Instances and Amount Invested (USD Million)
Figure 10.32. Debt Financing: Distribution of Amount Invested by Region
Figure 10.33. Debt Financing: Most Active Investors by Amount Invested
Figure 10.34. Capital Investments in RNA Therapeutics: Summary of Investments, 2011-2022
Figure 12.1. Arbutus Biopharma: Annual Revenues and Key Balance Sheet Parameter-related Trends, 2017-2022
Figure 12.2. Arbutus Biopharma: Liquidity Ratios, 2017-2022
Figure 12.3. Arbutus Biopharma: Financial and Business Risk Ratios and Turnover / Efficiency Ratios, 2017-2022
Figure 12.4. Arbutus Biopharma: Profitability Ratios, 2017-2022
Figure 12.5. Arbutus Biopharma: Market Value Ratios and Stability Ratios, 2017-2022
Figure 12.6. Arcturus Therapeutics: Stock Price (Candlestick Chart) and Volume Traded
Figure 12.7. Arcturus Therapeutics: 5-Day Moving Average
Figure 12.8. Arcturus Therapeutics: 10-Day Moving Average
Figure 12.9. Arcturus Therapeutics: 50-Day Moving Average
Figure 12.10. Arcturus Therapeutics: Bollinger Band
Figure 12.11. Arcturus Therapeutics: Relative Strength Index
Figure 12.12. Arcturus Therapeutics: Commodity Channel Index (CCI)
Figure 12.13. Arcturus Therapeutics: Moving Average Convergence / Divergence (MACD)
Figure 12.14. Arcturus Therapeutics: Williams' R Analysis
Figure 12.15. Arcturus Therapeutics: Average Directional Index (ADX)
Figure 13.1. Arbutus Biopharma: Company Fundamentals
Figure 13.2. Arbutus Biopharma: Trend of Stock Prices Since Initial Public Offering
Figure 13.3. Arcturus Therapeutics: Company Fundamentals
Figure 13.4. Arcturus Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.5. GreenLight Biosciences: Company Fundamentals
Figure 13.6. GreenLight Biosciences: Trend of Stock Prices Since Initial Public Offering
Figure 13.7. Gritstone bio: Company Fundamentals
Figure 13.8. Gritstone bio: Trend of Stock Prices Since Initial Public Offering
Figure 13.9. IVERIC bio: Company Fundamentals
Figure 13.10. IVERIC bio: Trend of Stock Prices Since Initial Public Offering
Figure 13.11. Moderna: Company Fundamentals
Figure 13.12. Moderna: Trend of Stock Prices Since Initial Public Offering
Figure 13.13. Omega Therapeutics: Company Fundamentals
Figure 13.14. Omega Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.15. Phio Pharmaceuticals: Company Fundamentals
Figure 13.16. Phio Pharmaceuticals: Trend of Stock Prices Since Initial Public Offering
Figure 13.17. Regulus Therapeutics: Company Fundamentals
Figure 13.18. Regulus Therapeutics: Trend of Stock Prices Since Initial Public Offering
Figure 13.19. Vir Biotechnology: Company Fundamentals
Figure 13.20. Vir Biotechnology: Trend of Stock Prices Since Initial Public Offering
Figure 14.1. Business Risk Assessment: Operations-related Risks
Figure 14.2. Business Risk Assessment: Business-related Risks
Figure 14.3. Business Risk Assessment: Financial / Asset-related Risks
Figure 14.4. Business Risk Assessment: Product / Technology-related Risks
Figure 14.5. Business Risk Assessment: Industry Specific Risks
Figure 14.6. Business Risk Assessment: Other Risks
Figure 14.7. Summary of Business Risk Assessment
Figure 15.1. RNA Therapeutics Market: Forecast, 2023-2035 (USD Million)
Figure 15.2. RNA Therapeutics Market: Distribution by Type of Therapy, 2023 and 2035
Figure 15.3. RNA Therapeutics Market for miRNA Therapies, 2023-2035 (USD Million)
Figure 15.4. RNA Therapeutics Market for siRNA Therapies, 2023-2035 (USD Million)
Figure 15.5 RNA Therapeutics Market for mRNA Therapies, 2023-2035 (USD Million)
Figure 15.6. RNA Therapeutics Market for mRNA Vaccines, 2023-2035 (USD Million)
Figure 15.7. RNA Therapeutics Market for RNA Aptamers, 2023-2035 (USD Million)
Figure 15.8. RNA Therapeutics Market: Distribution by Therapeutic Area, 2023 and 2035
Figure 15.9. RNA Therapeutics Market for Infectious Diseases, 2023-2035 (USD Million)
Figure 15.10. RNA Therapeutics Market for Metabolic Disorders, 2023-2035 (USD Million)
Figure 15.11. RNA Therapeutics Market for Oncological Disorders, 2023-2035 (USD Million)
Figure 15.12. RNA Therapeutics Market for Genetic Disorders, 2023-2035 (USD Million)
Figure 15.13. RNA Therapeutics Market for Other Disorders, 2023-2035 (USD Million)
Figure 15.14. RNA Therapeutics Market: Distribution by Route of Administration, 2023 and 2035
Figure 15.15. RNA Therapeutics Market for Intramuscular Therapies, 2023-2035 (USD Million)
Figure 15.16. RNA Therapeutics Market for Intravenous Therapies, 2023-2035 (USD Million)
Figure 15.17. RNA Therapeutics Market for Intranasal Therapies, 2023-2035 (USD Million)
Figure 15.18. RNA Therapeutics Market for Other Routes of Administration, 2023-2035 (USD Million)
Figure 15.19. RNA Therapeutics Market: Distribution by Key Geographies, 2023 and 2035
Figure 15.20. RNA Therapeutics Market in North America, 2023-2035 (USD Million)
Figure 15.21. RNA Therapeutics Market in Europe, 2023-2035 (USD Million)
Figure 15.22. RNA Therapeutics Market in Asia, 2023-2035 (USD Million)
Figure 15.23. RNA Therapeutics Market in Latin America, 2023-2035 (USD Million)
Figure 15.24. RNA Therapeutics Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 15.25. RNA Therapeutics Market in Rest of the World, 2023-2035 (USD Million)
Figure 16.1. Avidity Biosciences: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.2. BioNTech: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.3. GreenLight Biosciences: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.4. Gritstone bio: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.5. IVERIC bio: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.6. Moderna: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.7. Regulus Therapeutics: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 16.8. Vir Biotechnology: Returns on Investment Reported by Selected Stakeholders and Historical Funding Activity
Figure 17.1. Key Acquisition Targets: Comparison of Scores with Overall Dataset
Figure 17.2. Key Acquisition Targets: Comparison based on Qualifying Parameters (I/IV)
Figure 17.3. Key Acquisition Targets: Comparison based on Qualifying Parameters (II/IV)
Figure 17.4. Key Acquisition Targets: Comparison based on Qualifying Parameters (III/IV)
Figure 17.5. Key Acquisition Targets: Comparison based on Qualifying Parameters (IV/IV)
Figure 18.1. Concluding Landscape: North America
Figure 18.2. Concluding Landscape: Europe
Figure 18.3. Concluding Landscape: Asia and Rest of the World

Product Code: RAIS0108

INTRODUCTION

RNA therapeutics are known to target specific genetic sequences of individual patients, in order to provide more effective treatment options for a wide range of disorders, with fewer side effects. These therapies are currently being developed using different types of RNA-based molecules, including coding RNAs (such as mRNA) and non-coding RNAs (such as interfering RNAs (RNAi), antisense oligonucleotides (ASO) and RNA aptamers). The development of RNA-based therapeutics initially gained momentum in 2004, with the approval of the first RNA based therapeutic modality, Macugen (developed by Eyetech Pharmaceutics and Pfizer), which was intended for the treatment of neovascular age-related macular degeneration. However, despite the potential benefits offered by this therapeutic modality, the unique challenges associated with drug delivery, manufacturing, logistics and storage led to a decline in the popularity of RNA therapies post the initial rise in early 2000s. Consequently, some activity in this domain was reported in 2018, when ONPATTRO (developed by Alnylam Pharmaceuticals) received approval from USFDA and EMA; this RNAi therapy was intended for the treatment of hereditary transthyretin amyloidosis (hATTR), a rare and life-threatening disorder. , Subsequently, it was the phenomenal success of mRNA therapies against the COVID-19 pandemic which fully reignited the interest of general public, patients, healthcare providers and investors in this market. For instance, in 2021 and 2022, two mRNA vaccines intended for COVID-19 received emergency use approvals from the USFDA; these were BNT162b2 (developed by BioNTech and Pfizer) and mRNA-1273 (developed by Moderna). , In addition, RNA therapeutics have shown promising results in the treatment of rare diseases, particularly neurological and hepatic diseases. In fact, 80% of such therapies being evaluated in late stages of clinical development have received the orphan drug designation. This further showcases the potential of RNA therapeutics to actualize the concept of personalized medicine in the foreseen future.

RNA therapies have emerged as a promising treatment modality, with the potential to target and alter genes, modulate protein function and broaden the range of druggable targets, thereby, paving way for new avenues in disease diagnosis and treatment. Foreseeing these opportunities, numerous start-ups have been established in the last few years, indicating the growing interest in this sector. Owing to the rising demand for better therapeutic options and increasing adoption rate of such therapies, the investment focus for RNA therapeutics has increased significantly. In fact, since 2011, a total of over USD 16 billion was raised by RNA-based drug developers to advance their pipeline candidates. It is worth highlighting that, amongst the RNA therapeutics investors, majority of the investments have been led by mRNA vaccines investors and mRNA therapeutics investors. This is followed by RNAi therapeutics investors and RNA aptamers investors. Driven by the rise in government initiatives for early commercialization of pipeline therapeutics and active involvement of RNA therapeutics investors, we anticipate a variety of novel RNA based therapeutics to be developed, presenting lucrative investment opportunities for both short- and long-term investors.

SCOPE OF THE REPORT

"The Investor Series: Opportunities in RNA Therapeutics Market (mRNA Therapeutics and Vaccines, RNAi Therapeutics, and RNA Aptamers): Focus on Innovators Landscape, Analysis of Product Offerings and Company Health Indexing, Value Proposition Analysis, Company Competitiveness Analysis, Insights from Historical Funding and Investment Activity and Company Valuation, Financial Analysis and Business Risk Assessment of Key Public Ventures, Market Forecast and Opportunity Analysis, Analysis of Returns on Investment, Key Acquisition Targets)" report provides detailed information on the RNA therapeutics market, covering the various types of RNA therapeutics, including RNAi therapies, RNA aptamers, and mRNA therapies and vaccines. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, till 2035. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and a MS PowerPoint deck, which summarizes the key takeaways from the project and insights drawn from the curated data. Amongst other elements, the report includes:

An introduction to RNA therapeutics, highlighting information on products that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of RNA therapies, and the opinions of representatives from key stakeholder companies involved in this domain.
A detailed analysis of RNA therapeutics focused companies that were established post-2007, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size and type of venture.
An assessment of the various products, offered by innovator companies engaged in this domain, based on number of products and type of product. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on basic company details, product portfolio, financing activity, estimated revenues and profits) of different innovator companies, using a proprietary scoring criterion, which was informed via secondary research.
An informed perspective on the value proposition of companies captured in the report based on multiple relevant aspects, namely therapy-related aspect, developer-related aspect, technology-related aspect, and patient-related aspect.
A company competitiveness analysis, highlighting a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in the development of RNA therapeutics. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis.
A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of innovator companies mentioned in the report. Further, it features a list of leading investors in RNA therapeutics market, based on their participation in financing activity in this industry segment.
A proprietary analysis defining a basis for estimating the relative valuation of private companies, among the innovators discussed in this report. The value statements generated under this analytical framework were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were then extrapolated to generate the likely valuation estimates for all companies in the dataset.
An elaborate review of the overall RNA therapeutics market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset.
Elaborate profiles of the prominent public ventures engaged in the development of RNA therapeutics, featuring a brief overview of the company, details on its management team, insights generated from its balance sheet (if available), information on product portfolio, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis).
A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology-related risks, and industry specific risks and other risks (social, economic, environmental and political risks).
A detailed market forecast analysis, highlighting the likely evolution of the RNA therapeutics market in the short to mid-term and long term, over the period 2023-2035. Further the year-wise projections of the current and future opportunity have been segmented based on relevant parameters, such as type of therapy (miRNA therapies, siRNA therapies, mRNA therapies, mRNA vaccines and RNA aptamers), therapeutic area (infectious diseases, metabolic disorders, oncological disorders, genetic disorders, and other disorders), route of administration (intramuscular, intravenous, intranasal and other routes of administration and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world). In order to account for future uncertainties in the market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
A case study where investors have exited various RNA therapeutics-related ventures, offering insights on returns on investment received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the RNA therapeutics market.
A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. The information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

The insights presented are solely based on our knowledge, research and understanding of the relevant market, as inferred from various primary and secondary sources of information.

CHAPTER OUTLINES

EXCEL DELIVERABLES

Spreadsheet I include details on the companies captured in the report, along with their respective products. It also features proprietary company health indexing analysis, value proposition analysis, insights from a detailed company competitiveness analysis and a list of industry stakeholders that were deemed to be likely targets for mergers / acquisitions, in the near future. In addition, the deliverable includes a summary dashboard, featuring interactive graphical representations of key insights generated from the data collated.

Spreadsheet II features a summary dashboard, including interactive graphical representations of some of the key insights related to the capital investments made in the RNA therapeutics domain (since 2011).

Spreadsheet III showcases our proprietary company valuation analysis, wherein we have developed a proprietary model to extrapolate publicly information (related to valuation of specific companies) to develop informed estimates of the likely value of a company.

Spreadsheet IV is a collection of multiple MS Excel sheets that provides summary of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the innovator companies' dataset.

Spreadsheet V offers our independent perspective on the various types of risks (namely operations-related risks, business-related risks, financial / asset-related risks, product / technology-related risks, industry specific risks, and other risks) that the publicly listed ventures are presently exposed to; it includes a summary heat map representation that provides a pictorial perspective of the diversity and level of risks (as per our opinion), as well.

Spreadsheet VI includes publicly available information on the investments made by selected investors in companies that are now publicly listed. Based on the aforementioned data, we have offered a perspective on the likely returns on investments received by the mentioned investors.

Spreadsheet VII is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with the RNA therapeutics market.

POWERPOINT DELIVERABLES

Chapter 1 provides a brief summary of the content presented in the report, beginning with the trends associated with the rapidly growing RNA therapeutics market. Further, some of the key benefits associated with RNA therapeutics, have been presented. Finally, the chapter provides an overview of the current scenario, offering a perspective on how, in light of recent funding activity, the market is likely to evolve over the coming years.

Chapters 2 and 3 features a brief (pictorial) summary of the project objectives and approach used for data collection and analysis, in this study.

Chapter 4 features an executive summary of the key insights generated from the data and analytical outputs presented in the report.

Section I: Introduction to RNA Therapeutics and Innovators Landscape

Chapter 5 presents an introduction to RNA therapeutics, highlighting the background about the origin and evolution of this domain, along with benefits of such therapies. It features the key application areas of RNA therapeutics and vaccines, along with opinions of experts, describing various benefits of these therapies, and anticipated future challenges. Further, it includes information on some of the key players that are engaged in this domain. The views presented in this chapter are backed by inputs from representatives of key stakeholder companies (as stated in publicly available articles and validated through primary research). It concludes with a discussion on the prominent barriers to the development and success of RNA therapeutics.

Chapter 6 focuses on some of the innovators (companies established post-2007) and features a detailed analysis of such companies. Further, this section highlights important company related details, such as year of establishment, headquarters, company size, and type of venture.

Chapter 7 includes information on the various products developed by the companies captured in the report (listed in Chapter 6). Further, it features analysis based on number and types of therapy. Based on the aforementioned insights and details presented in Chapter 6, we have developed a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity and estimated revenues and profits) of the different innovator companies.

Chapter 8 offers an informed perspective on the apparent value proposition of the companies captured in the report (listed in Chapter 6). Based on multiple relevant inputs (as inferred from publicly disclosed value statements), namely therapy-related aspect, developer-related aspect, technology-related aspect and patient-related aspect, we developed an empirical framework to quantify the value proposition of a business.

Chapter 9 features a detailed company competitiveness analysis, offering a quantitative basis for comparing the developers of RNA therapeutics captured in this report. It is worth mentioning that the analysis described in this section is based on a proprietary scoring criterion, which was informed via our company health indexing and valuation exercise.

Section II: Analysis of Investments and Company Valuation

Chapter 10 offers insights from a detailed analysis of the funding and investment activity in this domain, since 2011. It includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies discussed in the report.

Chapter 11 features a proprietary basis for estimating the relative valuation of private companies, among the innovators discussed in this report. It is worth mentioning that the aforementioned estimations were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated to generate valuation estimates for all companies in the dataset.

Section III: Financial Analysis and Assessment of Business Risks

Chapter 12 is modelled in the likeness of an equity research report. It features a review of the overall RNA therapeutics market from a financial perspective and includes detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of publicly listed companies within the innovators landscape dataset.

Chapter 13 includes detailed profiles of the prominent public ventures engaged in the development of RNA therapeutics. Each profile features a brief overview of the company, details on its management team, insights from its balance sheet (if available), information on product portfolio, a section on recent developments and key financial details (including company investment highlights, company fundamental and company technical analysis).

Chapter 14 includes a case study on business risk assessment, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, financial / asset-related risks, product / technology-related risks, and industry specific risks and other risks (social, economic, environmental and political risks).

Section IV: Market Forecast and Opportunity Analysis

Chapter 15 features an insightful market forecast and opportunity analysis, highlighting the estimated current and future size of the overall RNA therapeutics market, during the period 2023-2035. The opportunity has been segregated based on type of therapy (miRNA therapies, siRNA therapies, mRNA therapies, mRNA vaccines and RNA aptamers), therapeutic area (infectious diseases, metabolic disorders, oncological disorders, genetic disorders, and other disorders), route of administration (intramuscular, intravenous, intranasal and other routes of administration) and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and rest of the world).

Section V: Analysis of Returns on Investment and Key Acquisition Targets

Chapter 16 includes a case study wherein the investors have exited various RNA therapeutics-based ventures, offering insights on returns on investment received (based on availability of data). The abovementioned estimates / details offer a perspective on how past investments have paid off for investors as company gradually went public, over time.

Chapter 17 offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in Section I), to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.

Chapter 18 provides a pictorial summary of the overall project, presenting insights on the market landscape, funding and investment activity, value proposition, key acquisition targets and the market opportunities in RNA therapeutics domain, across different global regions.

Chapter 19 is a set of appendices, that contains the table of contents, list of figures, tables, companies and organizations mentioned in the report.

EXCEL DELIVERABLE

1. INNOVATORS AND PRODUCTS DATASET

1.1. Analysis Notes
1.2. Innovators Landscape
1.3. Products Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. Appendices

2. FUNDING AND INVESTMENT ANALYSIS

2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in RNA Therapeutics
2.4 Appendices

3. COMPANY VALUATION ANALYSIS

3.1. Analysis Notes
3.2. Sample Data Analysis
3.3. Company Valuation
3.4. Appendices

4. FUNDAMENTAL FINANCIAL ANALYSIS

4.1. Analysis Notes
4.2. Summary Dashboard
4.3. Company Fundamentals
4.4. Fundamental Analysis
- 4.4.1. Financial Ratios
  - 4.4.4.1. Liquidity Ratios
  - 4.4.4.2. Financial and Business Risk Ratios
  - 4.4.4.3. Turnover / Efficiency Ratios
  - 4.4.4.4. Profitability Ratios
  - 4.4.4.4. Market Value Ratios
  - 4.4.4.5. Stability Ratios
4.5. Appendices

5. TECHNICAL FINANCIAL ANALYSIS

5.1. Analysis Notes
5.2. Key Highlights
5.3. Open High Low Close Chart / Stock Price & Volume Traded (Last 100 Days)
5.4. 5 Day Moving Average (Buy & Sell Signals)
5.5. 10 Day Moving Average (Buy & Sell Signals)
5.6. 50 Day Moving Average (Buy & Sell Signals)
5.7. Bollinger Bands®
5.8. Relative Strength Index
5.9. Average Directional Index
5.10. Commodity Channel Index
5.11. Williams R
5.12. Moving Average Convergence Divergence (MACD)
5.13. Appendices

6. BUSINESS RISK ASSESSMENT

6.1. Analysis Notes
6.2. Business Risk Data
6.3. Appendices

7. MARKET FORECAST AND OPPORTUNITY ANALYSIS

7.1. Analysis Notes
7.2. Market Forecast and Opportunity Analysis: Summary
7.3. Market Forecast and Opportunity Analysis: Base Scenario
7.4. Market Forecast and Opportunity Analysis: Conservative Scenario
7.5. Market Forecast and Opportunity Analysis: Optimistic Scenario

8. ANALYSIS OF RETURNS ON INVESTMENT

8.1. Analysis Notes
8.2. Estimated RoI for Investors in Company A
8.3. Estimated RoI for Investors in Company B
8.4. Estimated RoI for Investors in Company C

POWERPOINT DELIVERABLE

1. CONTEXT

2. PROJECT APPROACH

3. PROJECT OBJECTIVES

4. EXECUTIVE SUMMARY

Section I: Introduction to RNA Therapeutics and Innovators Landscape

5. THE RNA THERAPEUTICS MARKET

5.1. Overview
5.2. Types of RNA Therapeutics
5.3. Historical Development
5.4. Applications of RNA Therapeutics
5.5. Benefits of RNA Therapeutics
5.6. Challenges Associated with RNA Therapeutics
5.7. Contemporary Sentiments and Expert Opinions

6. RNA THERAPEUTICS: INNOVATORS LANDSCAPE

6.1. Methodology
6.2. Innovators in the RNA Therapeutics Market
6.3. Analysis of Innovators Landscape
6.4. Concluding Remarks

7. RNA THERAPEUTICS: PRODUCTS LANDSCAPE AND COMPANY HEALTH INDEXING

7.1. List of RNA Therapeutics
7.2. Analysis of Products Landscape
7.3. Company Health Indexing Methodology
7.4. Company Health Indexing Scoring
7.5. Company Health Indexing

8. VALUE PROPOSITION ANALYSIS

8.1. Overview and Methodology
8.2. Value Proposition Analysis: Therapy-related Aspect
8.3. Value Proposition Analysis: Developer-related Aspect
8.4. Value Proposition Analysis: Technology-related Aspect
8.5. Value Proposition Analysis: Patient-related Aspect
8.6. Concluding Remarks

9. COMPANY COMPETITIVENESS ANALYSIS

9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks

Section II: Analysis of Investments and Company Valuation

10. FUNDING AND INVESTMENT ANALYSIS

10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Companies
10.4. Analysis of Trends Associated with Individual Funding Categories
10.5. Funding and Investments Summary

11. COMPANY VALUATION ANALYSIS

11.1. Overview and Methodology
11.2. Valuation of Public Companies
11.3. Company Valuation: Based on Company Size
11.4. Company Valuation: Based on Latest Stage of Financing
11.5. Company Valuation: Based on Company Size and Latest Stage of Funding

Section III: Financial Analysis and Assessment of Business Risks

12. FINANCIAL ANALYSIS OF PUBLIC VENTURES

12.1. Fundamental Financial Analysis Overview
12.2. Financial Ratios (Interpretation Guide)
12.3. Fundamental Financial Analysis: List of Public Companies
12.4. Case Study 1
12.5. Technical Financial Analysis Overview
12.6. Technical Indicators (Interpretation Guide)
12.7. Technical Financial Analysis: List of Public Companies
12.8. Case Study 2

13. COMPANY PROFILES OF PUBLIC VENTURES

13.1. Arbutus Biopharma
- 13.1.1. Key Highlights
  - 13.1.1.1. Company Overview
  - 13.1.1.2. Insights from Balance Sheet
  - 13.1.1.3. Key Executive Team
  - 13.1.1.4. Recent Developments
- 13.1.2. Key Financial Details
  - 13.1.2.1. Company Investments
  - 13.1.2.2. Company Fundamentals
  - 13.1.2.3. Company Technicals
13.2. Arcturus Therapeutics
- 13.2.1. Key Highlights
  - 13.2.1.1. Company Overview
  - 13.2.1.2. Insights from Balance Sheet
  - 13.2.1.3. Key Executive Team
  - 13.2.1.4. Recent Developments
- 13.2.2. Key Financial Details
  - 13.2.2.1. Company Investments
  - 13.2.2.2. Company Fundamentals
  - 13.2.2.3. Company Technicals
13.3. GreenLight Biosciences
- 13.3.1. Key Highlights
  - 13.3.1.1. Company Overview
  - 13.3.1.2. Insights from Balance Sheet
  - 13.3.1.3. Key Executive Team
  - 13.3.1.4. Recent Developments
- 13.3.2. Key Financial Details
  - 13.3.2.1. Company Investments
  - 13.3.2.2. Company Fundamentals
  - 13.3.2.3. Company Technicals
13.4. Gritstone bio
- 13.4.1. Key Highlights
  - 13.4.1.1. Company Overview
  - 13.4.1.2. Insights from Balance Sheet
  - 13.4.1.3. Key Executive Team
  - 13.4.1.4. Recent Developments
- 13.4.2. Key Financial Details
  - 13.4.2.1. Company Investments
  - 13.4.2.2. Company Fundamentals
  - 13.4.2.3. Company Technicals
13.5. IVERIC bio
- 13.5.1. Key Highlights
  - 13.5.1.1. Company Overview
  - 13.5.1.2. Insights from Balance Sheet
  - 13.5.1.3. Key Executive Team
  - 13.5.1.4. Recent Developments
- 13.5.2. Key Financial Details
  - 13.5.2.1. Company Investments
  - 13.5.2.2. Company Fundamentals
  - 13.5.2.3. Company Technicals
13.6. Moderna
- 13.6.1. Key Highlights
  - 13.6.1.1. Company Overview
  - 13.6.1.2. Insights from Balance Sheet
  - 13.6.1.3. Key Executive Team
  - 13.6.1.4. Recent Developments
- 13.6.2. Key Financial Details
  - 13.6.2.1. Company Investments
  - 13.6.2.2. Company Fundamentals
  - 13.6.2.3. Company Technicals
13.7. Omega Therapeutics
- 13.7.1. Key Highlights
  - 13.7.1.1. Company Overview
  - 13.7.1.2. Insights from Balance Sheet
  - 13.7.1.3. Key Executive Team
  - 13.7.1.4. Recent Developments
- 13.7.2. Key Financial Details
  - 13.7.2.1. Company Investments
  - 13.7.2.2. Company Fundamentals
  - 13.7.2.3. Company Technicals
13.8. Phio Pharmaceuticals
- 13.8.1. Key Highlights
  - 13.8.1.1. Company Overview
  - 13.8.1.2. Insights from Balance Sheet
  - 13.8.1.3. Key Executive Team
  - 13.8.1.4. Recent Developments
- 13.8.2. Key Financial Details
  - 13.8.2.1. Company Investments
  - 13.8.2.2. Company Fundamentals
  - 13.8.2.3. Company Technicals
13.9. Regulus Therapeutics
- 13.9.1. Key Highlights
  - 13.9.1.1. Company Overview
  - 13.9.1.2. Insights from Balance Sheet
  - 13.9.1.3. Key Executive Team
  - 13.9.1.4. Recent Developments
- 13.9.2. Key Financial Details
  - 13.9.2.1. Company Investments
  - 13.9.2.2. Company Fundamentals
  - 13.9.2.3. Company Technicals
13.10. Vir Biotechnology
- 13.10.1. Key Highlights
  - 13.10.1.1. Company Overview
  - 13.10.1.2. Insights from Balance Sheet
  - 13.10.1.3. Key Executive Team
  - 13.10.1.4. Recent Developments
- 13.10.2. Key Financial Details
  - 13.10.2.1. Company Investments
  - 13.10.2.2. Company Fundamentals
  - 13.10.2.3. Company Technicals

14. BUSINESS RISK ASSESSMENT

14.1. Overview and Methodology
14.2. Operations-related Risks
14.3. Business-related Risks
14.4. Financial / Asset-related Risks
14.5. Product / Technology-related Risks
14.6. Industry Specific Risks
14.7. Other Risks
14.8. Summary of Business Risk Assessment

Section IV: Market Forecast and Opportunity Analysis

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

15.1. Overview and Methodology
15.2. Global RNA Therapeutics Market, 2023-2035
- 15.2.1. RNA Therapeutics Market: Analysis by Type of Therapy, 2023 and 2035
  - 15.2.1.1. RNA Therapeutics Market for miRNA Therapies, 2023-2035
  - 15.2.1.2. RNA Therapeutics Market for siRNA Therapies, 2023-2035
  - 15.2.1.3. RNA Therapeutics Market for mRNA Therapies, 2023-2035
  - 15.2.1.4. RNA Therapeutics Market for mRNA Vaccines, 2023-2035
  - 15.2.1.5. RNA Therapeutics Market for RNA Aptamers, 2023-2035
- 15.2.2. RNA Therapeutics Market: Analysis by Therapeutic Area, 2023 and 2035
  - 15.2.2.1. RNA Therapeutics Market for Infectious Diseases, 2023-2035
  - 15.2.2.2. RNA Therapeutics Market for Metabolic Disorders, 2023-2035
  - 15.2.2.3. RNA Therapeutics Market for Oncological Disorders, 2023-2035
  - 15.2.2.4. RNA Therapeutics Market for Genetic Disorders, 2023-2035
  - 15.2.2.5. RNA Therapeutics Market for Other Disorders, 2023-2035
- 15.2.3. RNA Therapeutics Market: Analysis by Route of Administration, 2023 and 2035
  - 15.2.3.1. RNA Therapeutics Market for Intramuscular Therapies, 2023-2035
  - 15.2.3.2. RNA Therapeutics Market for Intravenous Therapies, 2023-2035
  - 15.2.3.3 RNA Therapeutics Market for Intranasal Therapies, 2023-2035
  - 15.2.3.4 RNA Therapeutics Market for Other Routes of Administration, 2023-2035
- 15.2.4. RNA Therapeutics Market: Analysis by Key Geographies, 2023 and 2035
  - 15.2.4.1. RNA Therapeutics Market in North America, 2023-2035
  - 15.2.4.2. RNA Therapeutics Market in Europe, 2023-2035
  - 15.2.4.3. RNA Therapeutics Market in Asia, 2023-2035
  - 15.2.4.3. RNA Therapeutics Market in Latin America, 2023-2035
  - 15.2.4.3. RNA Therapeutics Market in Middle East and North Africa, 2023-2035
  - 15.2.4.3. RNA Therapeutics Market in Rest of the World, 2023-2035

Section V: Analysis of Returns on Investment and Key Acquisition Targets

16. ANALYSIS OF RETURNS ON INVESTMENT

16.1. Overview and Methodology
16.2. Case Studies
- 16.2.1. Avidity Biosciences
- 16.2.2. BioNTech
- 16.2.3. GreenLight Biosciences
- 16.2.4. Gritstone bio
- 16.2.5. IVERIC bio
- 16.2.6. Moderna
- 16.2.7. Regulus Therapeutics
- 16.2.8. Vir Biotechnology
16.3. Concluding Remarks

17. KEY ACQUISITION TARGETS

17.1. Overview
17.2. List of Key Acquisition Targets
17.3. Concluding Remarks

RNA治療薬市場（mRNA治療薬およびワクチン、RNAi治療薬、RNAアプタマー）における機会：イノベーター動向、製品オファリング分析、企業のヘルスインデックス、主な買収標的

Investor Series: Opportunities in RNA Therapeutics Market (mRNA Therapeutics & Vaccines, RNAi Therapeutics, & RNA Aptamers): Focus on Innovators Landscape, Analysis of Product Offerings & Company Health Indexing, Key Acquisition Targets

目次

EXCELの成果物

第1章 イノベーターと製品のデータセット

第2章 資金調達と投資分析

第3章 企業評価分析

第4章 基本的財務分析

第5章 技術的財務分析

第6章 ビジネスリスク評価

第7章 市場予測と機会分析

第8章 投資収益率の分析

Power Pointの成果物

第1章 概要

第2章 プロジェクトのアプローチ

第3章 プロジェクトの目的

第4章 エグゼクティブサマリー

第5章 RNA治療薬市場

第6章 RNA治療薬：イノベーターの情勢

第7章 RNA治療薬：製品の情勢と企業のヘルスインデックス

第8章 価値命題分析

第9章 企業の競争力分析

第10章 資金調達と投資分析

第11章 企業価値分析

第12章 公開ベンチャーの財務分析

第13章 パブリックベンチャーの企業プロファイル

第14章 ビジネスリスク評価

第15章 市場予測と機会分析

第16章 投資収益率の分析

第17章 主な買収対象

第18章 結論

第19章 付録

LIST OF TABLES

LIST OF FIGURES

INTRODUCTION

SCOPE OF THE REPORT

RESEARCH METHODOLOGY

CHAPTER OUTLINES

EXCEL DELIVERABLES

POWERPOINT DELIVERABLES

Section I: Introduction to RNA Therapeutics and Innovators Landscape

Section II: Analysis of Investments and Company Valuation

Section III: Financial Analysis and Assessment of Business Risks

Section IV: Market Forecast and Opportunity Analysis

Section V: Analysis of Returns on Investment and Key Acquisition Targets

TABLE OF CONTENTS

EXCEL DELIVERABLE

1. INNOVATORS AND PRODUCTS DATASET

2. FUNDING AND INVESTMENT ANALYSIS

3. COMPANY VALUATION ANALYSIS

4. FUNDAMENTAL FINANCIAL ANALYSIS

5. TECHNICAL FINANCIAL ANALYSIS

6. BUSINESS RISK ASSESSMENT

7. MARKET FORECAST AND OPPORTUNITY ANALYSIS

8. ANALYSIS OF RETURNS ON INVESTMENT

POWERPOINT DELIVERABLE

1. CONTEXT

2. PROJECT APPROACH

3. PROJECT OBJECTIVES

4. EXECUTIVE SUMMARY

5. THE RNA THERAPEUTICS MARKET

6. RNA THERAPEUTICS: INNOVATORS LANDSCAPE

7. RNA THERAPEUTICS: PRODUCTS LANDSCAPE AND COMPANY HEALTH INDEXING

8. VALUE PROPOSITION ANALYSIS

9. COMPANY COMPETITIVENESS ANALYSIS

10. FUNDING AND INVESTMENT ANALYSIS

11. COMPANY VALUATION ANALYSIS

12. FINANCIAL ANALYSIS OF PUBLIC VENTURES

13. COMPANY PROFILES OF PUBLIC VENTURES

14. BUSINESS RISK ASSESSMENT

15. MARKET FORECAST AND OPPORTUNITY ANALYSIS

16. ANALYSIS OF RETURNS ON INVESTMENT

17. KEY ACQUISITION TARGETS

18. CONCLUSION

19. APPENDICES

第1章イノベーターと製品のデータセット

第2章資金調達と投資分析

第3章企業評価分析

第4章基本的財務分析

第5章技術的財務分析

第6章ビジネスリスク評価

第7章市場予測と機会分析

第8章投資収益率の分析

第1章概要

第2章プロジェクトのアプローチ

第3章プロジェクトの目的

第4章エグゼクティブサマリー

第8章価値命題分析

第9章企業の競争力分析

第10章資金調達と投資分析

第11章企業価値分析

第12章公開ベンチャーの財務分析

第13章パブリックベンチャーの企業プロファイル

第14章ビジネスリスク評価

第15章市場予測と機会分析

第16章投資収益率の分析

第17章主な買収対象

第18章結論

第19章付録